SCHEMBL205216

SCHEMBL205216

O=C(O)C1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
NPC1 O15118 2/20 1.00
RAB9A P51151 2/20 1.00
CYP2C19 P33261 1/20 0.79
HTT P42858 1/20 0.65
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.61
ENPP2 Q13822 1/20 0.59
POLB P06746 1/20 0.58
GRIN2B Q13224 8/20 0.58
CYP2D6 P10635 4/20 0.57
CYP2C9 P11712 4/20 0.57
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
CYP3A4 P08684 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3097843 0.98 SMN1; SMN2 (0.97) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL31170269 0.94 SMN1; SMN2 (0.89) SMN1; SMN2NPC1RAB9ACYP2C19HTT
Bicarbonate SCHEMBL3906619 0.94 SMN1; SMN2 (0.89) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL895480 0.94 SMN1; SMN2 (0.89) SMN1; SMN2NPC1RAB9ACYP2C19HTT
Bicarbonate SCHEMBL3906615 0.94 SMN1; SMN2 (0.89) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL9571856 0.93 SMN1; SMN2 (0.87) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL31449815 0.93 SMN1; SMN2 (0.87) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL25030757 0.92 SMN1; SMN2 (0.85) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL12070966 0.91 SMN1; SMN2 (0.84) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL103560 0.91 SMN1; SMN2 (0.84) SMN1; SMN2NPC1RAB9ACYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113976072-B Preparation device and method of 4-formyl-N-CBZ piperidine 武汉青风凯默生物医药科技有限公司 2024-02-23 CN claimed
CN-113976072-A Preparation device and method of 4-formyl-N-CBZ piperidine 武汉青风凯默生物医药科技有限公司 2022-01-28 CN claimed
CN-112939748-A Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid 中国科学院大连化学物理研究所 2021-06-11 CN claimed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
EP-0597088-B1 NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS INST NAT SANTE RECH MED (FR) 2000-12-06 EP claimed
EP-0302788-B1 2-[Methyl(4-piperidinyl)]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b] indole derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1992-02-05 EP claimed
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2026-05-28 US disclosed
WO-2026103814-A1 IRREVERSIBLE FAP INHIBITOR AND USE THEREOF 南京科络思生物科技有限公司 2026-05-21 WO disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 EP disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
EP-4712961-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2026-03-25 EP disclosed
WO-1991019709-A1 IMIDAZOLYLBENZOYL SUBSTITUTED HETEROCYCLES SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-12-26 WO disclosed
US-4977159-A HYPOTENSIVE AGENTS SYNTHELABO (FR) 1990-12-11 US disclosed
US-4968798-A Liquid-crystalline, 1-substituted piperidine-4-carboxylic acid esters HOECHST AKTIENGESELLSCHAFT (DE) 1990-11-06 US disclosed
EP-0322724-A2 Liquid crystalline piperidine-4-carboxylic acid esters substituted in position 1, process for their preparation and their use in liquid crystalline mixtures HOECHST AKTIENGESELLSCHAFT (DE) 1989-07-05 EP disclosed
EP-0309422-A2 New amidino tricycle derivatives ISTITUTO DE ANGELI S.p.A. (IT) 1989-03-29 EP disclosed
EP-0000167-A1 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them. Krogsgaard-Larsen, Povl (DK) 1979-01-10 EP disclosed
US-4064255-A ANTIDEPRESSANTS MAR-PHA SOCIETE D'ETUDES ET D'EXPLOITATION DE MARQUES (FR) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF SGK1, PBK, SGK3 SMN1; SMN2 4675/4885NPC1 1814/4885RAB9A 1662/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD SMN1; SMN2 3901/4885NPC1 550/4885RAB9A 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.